After working with the Burdock Group to recently obtain a successful self-contained GRAS (Generally Recognized As Safe) determination for its oxalate-reducing enzyme, biotechnology company Captozyme licensed the rights for commercialization to Entring LLC, which will make it available for purchase this fall as a food ingredient. Consumers seeking a low-oxalate diet can add the virtually tasteless, odorless powder to a variety of oxalate-packed foods and beverages to help reduce the presence of the anti-nutrient.
Helena Cowley, CEO of Captozyme, which was named a GrowFL Company To Watch in 2017, was the company's first employee. She never set out to be an entrepreneur, but says the process of growing the company has certainly turned her into one.
Captozyme, a Gainesville-based biotechnology company, is among 50 statewide companies expected to see significant growth over the next several years. Captozyme was selected from more than 500 nominees for Florida Companies to WatchSM, a statewide program managed by economic development group GrowFL, in association with the Edward Lowe Foundation.
Nephure™, an oxalate degrading enzyme manufactured by Captozyme, has received self-affirmed GRAS (Generally Recognized as Safe) notification by an independent panel of experts through scientific procedure following stringent US Food and Drug Administration (FDA) safety criteria. The independent panel evaluated a comprehensive dossier of characterization data and safety studies and concluded that Nephure is safe for use as a food ingredient.
Upon graduating from the University of Florida’s Innovation Hub, local biotechnology company, Captozyme Inc., recently acquired a newly constructed facility to house their new headquarters at 1622 NW 55th Place. The company plans to consolidate all operations there during the coming months, and is proud to be part of the developing biotechnology scene of Gainesville.